Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition

Cancer Letters

Volumn 300, Issue 2, 2011, Pages 145-153

  Blanco Aparicio, Carmen ^a   Collazo, Ana María García ^a   Oyarzabal, Julen ^a   Leal, Juan F ^a   Albarán, María Isabel ^a   Lima, Francisco Ramos ^a   Pequeño, Belén ^a   Ajenjo, Nuria ^a   Becerra, Mercedes ^a   Alfonso, Patricia ^a   Reymundo, María Isabel ^a   Palacios, Irene ^a   Mateos, Genoveva ^a   Quiñones, Helena ^a   Corrionero, Ana ^a   Carnero, Amancio ^a   Pevarello, Paolo ^a   Lopez, Ana Rodríguez ^a   Fominaya, Jesús ^a   Pastor, Joaquín ^a   Bischoff, James R ^a   more..

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

AML; Kinase inhibitors; PI3K; Pim 1

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; ETP 39010; ETP 45299; IMIDAZOPYRIDINE DERIVATIVE; INITIATION FACTOR 4E BINDING PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE PIM 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; MANTLE CELL LYMPHOMA; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN PROCESSING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; IMMUNOBLOTTING; INDAZOLES; LEUKEMIA, MYELOID, ACUTE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-PIM-1; PYRIDAZINES; SULFONAMIDES;

EID: 78649629111     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.09.016     Document Type: Article

References (39)

1. Cuypers H.T., Selten G., Quint W., Zijlstra M., Maandag E.R., Boelens W., van Wezenbeek P., Melief C., Berns A. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984, 37:141-150.
2. Selten G., Cuypers H.T., Berns A. Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J. 1985, 4:1793-1798.
3. van Lohuizen M., Verbeek S., Krimpenfort P., Domen J., Saris C., Radaszkiewicz T., Berns A. Predisposition to lymphomagenesis in Pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989, 56:673-682.
4. Selten G., Cuypers H.T., Boelens W., Robanus-Maandag E., Verbeek J., Domen J., van Beveren C., Berns A. The primary structure of the putative oncogene Pim-1 shows extensive homology with protein kinases. Cell 1986, 46:603-611.
5. Wang Z., Bhattacharya N., Weaver M., Petersen K., Meyer M., Gapter L., Magnuson N.S. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J. Vet. Sci. 2001, 2:167-179.
6. Hoover D., Friedmann M., Reeves R., Magnuson N.S. Recombinant human Pim-1 protein exhibits serine/threonine kinase activity. J. Biol. Chem. 1991, 266:14018-14023.
7. Mikkers H., Nawijn M., Allen J., Brouwers C., Verhoeven E., Jonkers J., Berns A. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol. Cell Biol. 2004, 24:6104-6115.
8. Amson R., Sigaux F., Przedborski S., Flandrin G., Givol D., Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc. Natl. Acad. Sci. USA 1989, 86:8857-8861.
9. Brault L., Gasser C., Bracher F., Huber K., Knapp S., Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010, 95:1004-1015.
10. Hsi E.D., Jung S.H., Lai R., Johnson J.L., Cook J.R., Jones D., Devos S., Cheson B.D., Damon L.E., Said J. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a cancer and leukemia group B 59909 correlative science study. Leukemia Lymphoma 2008, 49:2081-2090.
11. Chen J., Kobayashi M., Darmanin S., Qiao Y., Gully C., Zhao R., Kondo S., Wang H., Yeung S.C., Lee M.H. Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation. Am. J. Pathol. 2009, 175:400-411.
12. Warnecke-Eberz U., Bollschweiler E., Drebber U., Metzger R., Baldus S.E., Holscher A.H., Monig S. Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res. 2009, 29:4451-4455.
13. Xu Y., Zhang T., Tang H., Zhang S., Liu M., Ren D., Niu Y. Overexpression of PIM-1 is a potential biomarker in prostate carcinoma. J. Surg. Oncol. 2005, 92:326-330.
14. Wang J., Kim J., Roh M., Franco O.E., Hayward S.W., Wills M.L., Abdulkadir S.A. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 2009, 29:2477-2487.
15. Willert M., Augstein A., Poitz D.M., Schmeisser A., Strasser R.H., Braun-Dullaeus R.C. Transcriptional regulation of Pim-1 kinase in vascular smooth muscle cells and its role for proliferation. Basic Res. Cardiol. 2009, 105:267-277.
16. Lilly M., Sandholm J., Cooper J.J., Koskinen P.J., Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 1999, 18:4022-4031.
17. Aho T.L., Sandholm J., Peltola K.J., Mankonen H.P., Lilly M., Koskinen P.J. Pim-1 kinase promotes inactivation of the pro-apoptotic bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004, 571:43-49.
18. Macdonald A., Campbell D.G., Toth R., McLauchlan H., Hastie C.J., Arthur J.S. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol. 2006, 7:1.
19. Gu J.J., Wang Z., Reeves R., Magnuson N.S. PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Oncogene 2009, 28:4261-4271.
20. Mochizuki T., Kitanaka C., Noguchi K., Muramatsu T., Asai A., Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J. Biol. Chem. 1999, 274:18659-18666.
21. Wang Z., Bhattacharya N., Mixter P.F., Wei W., Sedivy J., Magnuson N.S. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim. Biophys. Acta 2002, 1593:45-55.
22. Zhang Y., Wang Z., Magnuson N.S. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol. Cancer Res. 2007, 5:909-922.
23. Morishita D., Katayama R., Sekimizu K., Tsuruo T., Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008, 68:5076-5085.
24. Zippo A., De Robertis A., Serafini R., Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat. Cell Biol. 2007, 9:932-944.
25. Fox C.J., Hammerman P.S., Thompson C.B. The Pim kinases control rapamycin-resistant T cell survival and activation. J. Exp. Med. 2005, 201:259-266.
26. Hammerman P.S., Fox C.J., Birnbaum M.J., Thompson C.B. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005, 105:4477-4483.
27. Chen W.W., Chan D.C., Donald C., Lilly M.B., Kraft A.S. Pim family kinases enhance tumor growth of prostate cancer cells. Mol. Cancer Res. 2005, 3:443-451.
28. Grundler R., Brault L., Gasser C., Bullock A.N., Dechow T., Woetzel S., Pogacic V., Villa A., Ehret S., Berridge G., Spoo A., Dierks C., Biondi A., Knapp S., Duyster J., Schwaller J. Dissection of PIM serine/threonine kinases in FLT 3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J. Exp. Med. 2009, 206:1957-1970.
29. Qian K.C., Wang L., Hickey E.R., Studts J., Barringer K., Peng C., Kronkaitis A., Li J., White A., Mische S., Farmer B. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J. Biol. Chem. 2005, 280:6130-6137.
30. Bullock A.N., Debreczeni J., Amos A.L., Knapp S., Turk B.E. Structure and substrate specificity of the Pim-1 kinase. J. Biol. Chem. 2005, 280:41675-41682.
31. Bullock A.N., Debreczeni J.E., Fedorov O.Y., Nelson A., Marsden B.D., Knapp S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J. Med. Chem. 2005, 48:7604-7614.
32. Pogacic V., Bullock A.N., Fedorov O., Filippakopoulos P., Gasser C., Biondi A., Meyer-Monard S., Knapp S., Schwaller J. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res. 2007, 67:6916-6924.
33. Chen L.S., Redkar S., Bearss D., Wierda W.G., Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009, 114:4150-4157.
34. Mumenthaler S.M., Ng P.Y., Hodge A., Bearss D., Berk G., Kanekal S., Redkar S., Taverna P., Agus D.B., Jain A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol. Cancer Ther. 2009, 8:2882-2893.
35. Link W., Oyarzabal J., Serelde B.G., Albarran M.I., Rabal O., Cebria A., Alfonso P., Fominaya J., Renner O., Peregrina S., Soilan D., Ceballos P.A., Hernandez A.I., Lorenzo M., Pevarello P., Granda T.G., Kurz G., Carnero A., Bischoff J.R. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J. Biol. Chem. 2009, 284:28392-28400.
36. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
37. Lin Y.W., Beharry Z.M., Hill E.G., Song J.H., Wang W., Xia Z., Zhang Z., Aplan P.D., Aster J.C., Smith C.D., Kraft A.S. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2009, 115:824-833.
38. Folkes A.J., Ahmadi K., Alderton W.K., Alix S., Baker S.J., Box G., Chuckowree I.S., Clarke P.A., Depledge P., Eccles S.A., Friedman L.S., Hayes A., Hancox T.C., Kugendradas A., Lensun L., Moore P., Olivero A.G., Pang J., Patel S., Pergl-Wilson G.H., Raynaud F.I., Robson A., Saghir N., Salphati L., Sohal S., Ultsch M.H., Valenti M., Wallweber H.J., Wan N.C., Wiesmann C., Workman P., Zhyvoloup A., Zvelebil M.J., Shuttleworth S.J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 2008, 51:5522-5532.
39. Beharry Z., Zemskova M., Mahajan S., Zhang F., Ma J., Xia Z., Lilly M., Smith C.D., Kraft A.S. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol. Cancer Ther. 2009, 8:1473-1483.